Aton gains marketing rights for Lodosyn

LAWRENCEVILLE, N.J. Aton Pharma has acquired rights to a Parkinson’s disease drug from Bristol-Myers Squibb, Aton said.

Aton announced that it acquired U.S. marketing rights to Lodosyn (carbidopa) tablets, used with carbidopa-levodopa or levodopa to treat symptoms of Parkinson’s.

“The acquisition of Lodosyn continues our mission to improve patient outcomes and quality of life by providing medically essential therapeutics while enabling us to enter an important market,” Aton CEO Michael Wells said. “Nearly 1 million people in the U.S. are living with Parkinson’s.”